Table 1 Clinical information of the NSCLC patients (n = 20).
Age (years), median (range) | 69 (53– 79) | |
|---|---|---|
Observation time (months), median (range) | 25.5 (11.5–55.8) | |
Sex, N (%) | Male | 17 (85) |
Female | 3 (15) | |
Histology, N (%) | Adenocarcinoma | 8 (40) |
Squamous cell carcinoma | 11 (55) | |
NSCLC NOS | 1 (5) | |
Molecular alteration, N (%) | Wild type | 17 (85) |
KRAS mutation | 1 (5) | |
ROS1 fusion | 1 (5) | |
not assessed | 1 (5) | |
Disease stage, N (%) | IIB | 4 (20) |
IIIA | 7 (35) | |
IIIB | 6 (30) | |
IIIC | 3 (15) | |
ECOG PS, N (%) | 0 | 15 (75) |
1 | 5 (25) | |
Smokers, N (%) | Non-smoker | 1 (5) |
Smoker | 19 (95) | |
PD-L1 (TPS), N (%) | ≥ 50% | 6 (30) |
1–49% | 9 (45) | |
< 1% | 4 (20) | |
not assessed | 1 (5) | |
Radiotherapy, N (%) | 60 Gy in 30 fractions | 20 (100) |
Regimen of chemotherapy, N (%) | CDDP + VNR q3w | 8 (40) |
CBDCA + PTX weekly | 10 (50) | |
CBDCA + S-1 q3w | 2 (10) | |
Cycles of Durvalmab, N (%) | 1–5 | 4 (20) |
6–15 | 7 (35) | |
completed | 9 (45) | |
Clinical outcomes | CR (recurrence-free) | 9 (45) |
PD (local recurrence or distant metastasis) | 11 (55) | |
Radiation pneumonitis, N (%) | Grade 0–1 | 15 (75) |
Grade 2 | 5 (25) | |
irAE (Thyroiditis), N (%) | Grade 0 | 18 (90) |
Grade 1 | 1 (5) | |
Grade 2 | 1 (5) |
